Unlock instant, AI-driven research and patent intelligence for your innovation.

Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases

An inflammatory skin, cannabinoid technology, used in skin diseases, anti-inflammatory agents, non-central pain relievers, etc., can solve problems such as stiffness, pigmentation changes, aging skin, etc.

Active Publication Date: 2019-12-06
BOTANIX PHARMA LTD
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the skin in this area is likely to develop the features of aging skin, including noticeable wrinkling, skin thinning, stiffness, and / or dryness, and possible pigmentation changes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
  • Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
  • Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0239] Exemplary techniques for determining the permeability of compositions comprising cannabidiol.

[0240] The permeability of human skin has been studied for decades. The skin consists of two main layers, the outer epidermis and the inner dermis. The stratum corneum ("SC") is the outermost 10-20 μm of the epidermis and is responsible for the skin's great diffusion resistance to transdermal delivery of most drugs. Most skin enzyme activity is dependent on the basal cell layer of the living epidermis. Fibrous collagen is the main structural component of the dermis. Skin vasculature is supported by this collagen and lies a few micrometers below the epidermis. Basically, penetration ends here and systemic uptake begins. Many researchers have established skin permeability relationships based on the physicochemical parameters of skin penetrants (molecular weight, molecular volume, lipophilicity, hydrogen bond potential, polarity, etc.). However, when dealing with the transd...

Embodiment 2

[0247] Purpose:

[0248] Formulations of cannabidiol with silicone and other excipients are prepared.

[0249] Methods and results:

[0250] First, the solubility of cannabidiol (CBD) was assessed. The powder appears granular under the microscope. The solubility (w / w) of CBD in hexamethyldisiloxane (HDS) and mineral oil is less than about 3-4%. Although the reported solubility in ethanol is 3.5%, the solubility in propylene glycol (PG) and ethanol is about 6-7%. Solubility in oleyl alcohol (OA) was greater than 8% (did not trend higher in the study) and in isopropanol (IPA) was greater than 14%. Solubility studies concluded that OA and IPA are very good solvents, surprisingly IPA is much better than ethanol. Solubility in HDS and mineral oil is low, so fully non-polar solvents do not dissolve high levels of CBD well, but adding the OH groups present in fatty alcohols does increase CBD solubility.

[0251] Second, CBD is dissolved in a medium concentration in a highly vol...

Embodiment 3

[0275] Purpose:

[0276] Other formulations of cannabidiol with silicone and other excipients were prepared.

[0277] method:

[0278] CBD2 is an off-white crystalline powder that produces a clear solution in stark contrast to the CBD1 solution, which changes color by the end of the day. None of the CBD2 solutions had changed color and appeared clear by the end of day 1. CBD2 material dissolves like CBD1, so CBD2 is CBD without the color-changing properties of CBD1.

[0279] preparation

[0280] Formulation A (Type A)

[0281] 5%CBD / 2.5%HDA / 1%PMS / 91.5%HDS

[0282] Acne "spray" formulation A-7 was repeated and it behaved the same except it did not have any discoloration and was clear. It showed no signs of discolouration by the end of the day.

[0283] Tests performed:

[0284] a) Put a drop on the microscope slide, covering about 1cm 2 , no crystals appeared, but crystals did appear when rubbed vigorously with a finger (which caused crystal growth) later in the day (a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition comprising a cannabinoid and a siloxane, wherein the cannabinoid is dissolved in the composition.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for the delivery of cannabinoids. The pharmaceutical compositions of the invention are particularly suitable for use in the treatment of inflammatory skin disorders. Background technique [0002] The following discussion of the background art is intended only to aid in the understanding of the present invention. The discussion is not an acknowledgment or admission that any of the material referred to is or was common general knowledge before the priority date of the application. [0003] The skin of most mammals, including human skin, consists of three layers: (i) the epidermis, which is mainly composed of keratinocytes with a small number of melanocytes and Langerhans cells (antigen-presenting cells); (ii) the dermis , which contains nerve endings, sweat and oil (sebaceous) glands, hair follicles, and blood vessels, and is composed primarily of fibroblasts; and (iii) the deeper subcutaneo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/05A61P29/00A61P17/00
CPCA61K31/05A61K31/352A61P17/00A61P29/00A61K47/34A61K9/0014A61K9/7015A61K2300/00A61K9/08A61K47/24
Inventor E.库珀M.卡拉汉
Owner BOTANIX PHARMA LTD